Perspective Therapeutics, Inc. Logo

Perspective Therapeutics, Inc.

Developing targeted alpha radiotherapies using lead-212 to image and treat solid tumors.

CATX | US

Overview

Corporate Details

ISIN(s):
US46489V1044 (+1 more)
LEI:
Country:
United States of America
Address:
2401 ELLIOTT AVENUE, 98121 SEATTLE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company pioneering advanced treatments for cancer. The company specializes in developing image-guided, targeted alpha-particle therapies (TATs). Its proprietary technology platform uses a revolutionary lead-212 (Pb-212) based approach, conjugating radioisotopes to high-affinity targeting peptides. This theranostic method allows physicians to first image tumors to confirm targets and then deliver potent, short-range alpha radiation directly to cancer cells, aiming to maximize efficacy while minimizing damage to surrounding healthy tissue. The company's clinical pipeline is focused on oncology, with programs targeting melanoma, neuroendocrine tumors, and other solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Perspective Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Perspective Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Perspective Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan 4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America IBO
Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America INCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.